Organized by IFPMA – representing the global innovative biopharmaceutical industry committed to addressing the novel coronavirus public health crisis.
Read moreThis was originally published on Global Cause on the 2020 HIV & TB Awareness campaign on 1 December 2020. As the global coronavirus pandemic continues, we need to maintain continued access to HIV and TB essential medications worldwide. The COVID-19 pandemic has claimed more than 1.2 million lives, and many more deaths have likely gone unreported....
Read more20 November 2020, The World Health Organization, the Food and Agriculture Organization and the World Organization for Animal Health announced today the creation of the One Health Global Leaders Group on Antimicrobial Resistance (Global Leaders Group). This new United Nations high-level group will include Kenneth Frazier, Chairman of the board and chief executive officer at...
Read more18-24 November 2020 World Antimicrobial Awareness Week (WAAW) aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of drug-resistant infections. The International Society for Quality in Health Care (ISQua), the...
Read moreFor World Antimicrobial Awareness Week (WAAW), Dr Cary Adams shares with us the importance of raising awareness on the growing threat of antimicrobial resistance and how it affects the cancer community. In what circumstances and how often are antibiotics used for cancer treatment and care? The treatment and care of cancer involves a wide range...
Read moreGeneva 10 November 2020 – On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies delivered a statement declaring their shared commitment to equitable access to COVID-19 medicines and vaccines. In their joint statement, the two global pharmaceutical industry bodies acknowledge their responsibility and commitment to support...
Read moreIFPMA Statement for the resumed 73rd WHA on agenda item 13.2 WHO’s work in health emergencies We are fully committed to the principles of global equitable access to COVID-19 medicines and vaccines The biopharmaceutical –and pharmaceutical industries are committed to the principles of global equitable access to COVID-19 medicines and vaccines. Our global community is...
Read moreIFPMA very much welcomes the holistic approach of WHO to influenza preparedness. We acknowledge that a well performing GISRS, implementation of the Global Influenza Strategy 2019-2030 and ensuring the success of the PIP Framework’s objectives are key to this preparedness. IFPMA would also like to fully support WHO’s call for further sensitizing Member States to...
Read moreDame Sally Davies, UK AMR Special Envoy and Thomas Cueni, IFPMA’s DG have shared platforms on panels. This time at the World AMR Congress, saw the duo in a different format, with Dame Sally pitching questions at Thomas Cueni and asking him if industry has done enough to tackle AMR. Global Health Matters has reproduced...
Read morehttps://www.flipsnack.com/DukeNUSCoRE/core-regulatory-systems-strengthening.html
Read moreWatch full interview hereThomas Cueni, IFPMA Director General, spoke to Al Jazeera English, on the side lines of the World Health Summit, about collaboration between the pharmaceutical industry and governments to make sure COVID 19 vaccines are available in poorer countries; as well as industry’s commitment to the most rigorous regulatory scrutiny. Maryam Nemazee Also...
Read more